阿西替尼
医学
肾细胞癌
内科学
肿瘤科
第二线
多中心研究
回顾性队列研究
第一行
舒尼替尼
随机对照试验
作者
Jiwei Huang,Guohai Shi,Yueming Wang,Ping Wang,Jin Zhang,Wen Kong,Yong Huang,Shuo Wang,Wei Xue
出处
期刊:Future Oncology
[Future Medicine]
日期:2022-02-01
卷期号:18 (12): 1461-1471
被引量:3
标识
DOI:10.2217/fon-2021-1267
摘要
Aim: To evaluate the efficacy and safety of second-line treatment with axitinib plus toripalimab in patients with metastatic renal cell carcinoma and failure of VEGFR tyrosine kinase inhibitors. Methods: Data were collected restropectively. Kaplan–Meier analysis and Cox proportional hazards model determined the efficacy outcomes. Results: In 57 patients, objective response rate was 31.6% and median progression-free survival (PFS) was 11.7 months, while median overall survival was not reached. Median PFS was not reached in favorable-risk patients, whereas PFS of 11.0 and 7.8 months were observed in intermediate- and poor-risk patients, respectively (p = 0.011). The treatment-related toxicities were mild in nature. Conclusion: Second-line therapy with axitinib plus toripalimab provided durable response rate, longer PFS and a tolerable safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI